Publications by authors named "Sydney A Caputo"
Article Synopsis
- The study focuses on metastatic castration-resistant prostate cancer (mCRPC) that is resistant to androgen receptor signaling inhibitors, which is often lethal, and aims to investigate liquid biopsy biomarkers related to this disease.
- Researchers analyzed cell-free DNA and methylation from 126 mCRPC patients and developed a "stem-like" signature through RNA sequencing from both single cells and bulk samples.
- Findings indicated that specific alterations in cell-free DNA correlated with poorer patient outcomes, and an increase in stemness-associated traits in lethal mCRPC patients suggests a reprogramming mechanism that contributes to the aggressiveness of the cancer.
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms are ill-understood. Here, we applied deep sequencing to ∼100 mCRPC patients prior to the initiation of first-line AR-targeted therapy, which detected /enhancer alterations in over a third of patients, which correlated with lethality.
View Article and Find Full Text PDFA 75-year-old man with a history of previously treated localized prostate cancer and prostate-specific antigen of 4.86 ng/mL was referred for a 68 Ga-prostate-specific membrane antigen PET/CT. PET imaging was reported to be negative.
View Article and Find Full Text PDFArticle Synopsis
- African American men are diagnosed with and die from prostate cancer at higher rates than Caucasian men, and genetic differences, specifically higher rates of CDK12 somatic mutations, may contribute to this disparity.
- A study analyzing ctDNA in metastatic castration-resistant prostate cancer (mCRPC) between these two groups found that African American men exhibited significantly more pathogenic mutations and frameshift mutations after treatment with abiraterone and/or enzalutamide.
- The results suggest that the genetic differences observed in African American men could have implications for targeted treatments and personalized medicine in managing prostate cancer.
A 61-year-old man underwent a piflufolastat 18 F prostate-specific membrane antigen (PSMA) PET/CT scan due to a rising prostate-specific antigen level. The scan noted a focal cortical erosion on the CT scan in the right anterolateral tibia, and the PET showed an SUV max of 4.08.
View Article and Find Full Text PDFBackground: Bipolar androgen therapy (BAT) is a novel therapy known to be effective in a subset of men with metastatic castrate resistant prostate cancer (mCRPC). A better understanding of responders and nonresponders to BAT would be useful to clinicians considering BAT therapy for patients. Herein we analyze clinical and genetic factors in responders/nonresponders to better refine our understanding regarding which patients benefit from this innovative therapy.
View Article and Find Full Text PDFAn 84-year-old man with nonmetastatic castrate-sensitive prostate cancer was referred for a 68Ga-prostate-specific membrane antigen (PSMA) PET/CT scan with a prostate-specific antigen level of 3.6 ng/mL for restaging. He was 22 years post-radical prostatectomy and had salvage radiation being managed with intermittent hormonal therapy.
View Article and Find Full Text PDFBackground: The outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have significantly improved through treatment intensification, yet Black representation in those studies is suboptimal.
Methods: A multi-institutional, retrospective analysis of Black men with mHSPC was conducted, focusing on baseline demographics, treatment patterns, genomic profiles, clinical outcomes including prostate-specific antigen response, time to castrate-resistant prostate cancer (CRPC), and subsequent treatments.
Results: A total of 107 patients, median age 64 years, 62% with de novo metastases at diagnosis and 64% with high-volume disease, were included.